First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence
Author Information
Author(s): Sandercock J, Parmar M K B, Torri V, Qian W
Primary Institution: Department of Public Health and Epidemiology, University of Birmingham, Birmingham, UK
Hypothesis
What explains the heterogeneity in results from trials comparing paclitaxel/platinum combinations with platinum-based control treatments?
Conclusion
Single agent carboplatin is a safe and effective first-line treatment for women with advanced ovarian cancer.
Supporting Evidence
- The study represents around 88% of patients randomized into known trials of this question.
- Only one explanation for the heterogeneity was consistent with the results: differences in effectiveness of the control arms.
- The pooled result for progression-free survival showed a statistically significant benefit for paclitaxel/platinum.
- Statistical heterogeneity was observed in the results of the trials.
Takeaway
This study looked at different treatments for ovarian cancer and found that using carboplatin alone is a good option for patients.
Methodology
The study analyzed results from four large randomized trials comparing paclitaxel/platinum combinations with various control treatments.
Potential Biases
Potential bias due to differences in control regimens used across trials.
Limitations
The study is based on published trial data, which may not capture all relevant information.
Participant Demographics
The trials included a diverse group of women with advanced ovarian cancer.
Statistical Information
P-Value
0.0003
Confidence Interval
(0.80, 0.94)
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website